API SUPPLIERS

API Suppliers

25

US DMFs Filed

16

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

87

API Market Place

14

INTERMEDIATES

5

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

108.00

Annual Reports

0

FDF Market Place

5

EXCIPIENTS

259

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

2

News

21

REF STANDARD

EDQM

4

USP

3

JP

0

Other Listed Suppliers

4

SERVICES

0

Full Screen View

AIIMS

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

AIIMS Researchers Find Ayurvedic-Allopathic Combo BGR-34 & Glibenclamide in Controlling Diabetes

Details:

In the Animal experimental study, doctors have found that the pace of diabetes growth can be halted if allopathic drug is integrated with BGR-34, a herbal formulation enriched with antioxidant properties which stops bad cholesterol from accumulating in the heart arteries.

Lead Product(s): BGR-34,Glibenclamide

Therapeutic Area: Endocrinology Product Name: BGR-34

Highest Development Status: ApprovedProduct Type: Undisclosed

Partner/Sponsor/Collaborator: CSIR

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 03, 2021

ASK
US

Upload
your Marketing & Sales content

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Find Drugs in Development News & Deals for Glibenclamide

Glibenclamide

Glibenclamide

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

25 API Suppliers

16 USDMF

9 CEP/COS

4 JDMF

6 EU WC

1 KDMF

6 NDC API

12 Listed Suppliers

DEVELOPMENTS

1 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

5 Suppliers

DOSSIERs // Finished Dosage Formulations

184 Dossiers

83 FDA Orange Book

29 Europe

9 Canada

1 Australia

19 South Africa

43 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 1.25MG

TABLET;ORAL - 2.5MG

TABLET;ORAL - 5MG

TABLET;ORAL - 1.25MG;250MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 2.5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 5MG;500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

Suppliers

36 Kerry

27 BASF

18 Roquette

14 Corel Pharma Chem

13 Seppic

13 Microlex e.U

12 Sigachi Industries

11 Gangwal Chemicals

9 Gangwal Healthcare

9 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

7 SPI Pharma

7 DFE Pharma

6 Boai NKY Pharmaceuticals Ltd

6 Lonza Capsugel

6 Nanjing Well Pharmaceutical

6 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

6 Ideal Cures Pvt Ltd

5 Actylis

4 Prachin Chemical

4 Vasa Pharmachem

4 Ingredion Pharma Solutions

3 Kima Chemical

3 Pharmatrans-Sanaq

3 DKSH

3 Ulanqab Kema New Material

2 The Dow Chemical Company

2 Aeon Procare

2 Seqens

2 Finar

2 Clariant

2 Evonik

2 Jai Radhe Sales

2 Nomisma Healthcare

1 Qualicaps

1 Avesta Pharma

1 Qianhao Chemical (Hebei) Co., Ltd

1 Shanghai Welltone Material Technology Co., Ltd

1 Alcedo Pharmachem

1 Huzhou Sunflower Pharmaceutical Co. Ltd

TABLET;ORAL - 1.25MG;250MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 2.5MG;500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 5MG;500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons